# Erik A. Imel

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/erik-a-imel/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,271 |
| Field | Parathyroid Disorders and Treatments |
| h-index | 45 |
| i10-index | 87 |
| Last Known Institution | Indiana University Health |
| OpenAlex ID | https://openalex.org/A5009292672 |
| ORCID iD | 0000-0002-7284-3467 |
| Works | 226 |

## Researcher papers

- [A clinician's guide to X-linked hypophosphatemia](https://scholariq.org/papers/a-clinician-s-guide-to-x-linked-hypophosphatemia/)
- [Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects](https://scholariq.org/papers/establishment-of-sandwich-elisa-for-soluble-alpha-klotho-measurement-age/)
- [A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis](https://scholariq.org/papers/a-homozygous-missense-mutation-in-human-klotho-causes-severe-tumoral-calcinosis/)
- [Burosumab Therapy in Children with X-Linked Hypophosphatemia](https://scholariq.org/papers/burosumab-therapy-in-children-with-x-linked-hypophosphatemia/)
- [Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial](https://scholariq.org/papers/burosumab-versus-conventional-therapy-in-children-with-x-linked/)
- [A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis](https://scholariq.org/papers/a-randomized-double-blind-placebo-controlled-phase-3-trial-evaluating-the/)
- [Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia](https://scholariq.org/papers/randomized-trial-of-the-anti-fgf23-antibody-krn23-in-x-linked-hypophosphatemia/)
- [Iron Modifies Plasma FGF23 Differently in Autosomal Dominant Hypophosphatemic Rickets and Healthy Humans](https://scholariq.org/papers/iron-modifies-plasma-fgf23-differently-in-autosomal-dominant-hypophosphatemic/)
- [Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia](https://scholariq.org/papers/effects-of-iron-isomaltoside-vs-ferric-carboxymaltose-on-hypophosphatemia-in/)
- [Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia](https://scholariq.org/papers/sensitivity-of-fibroblast-growth-factor-23-measurements-in-tumor-induced/)
- [Unusual Cortical Phenotype After Hematopoietic Stem Cell Transplantation in a Patient With Osteopetrosis](https://scholariq.org/papers/unusual-cortical-phenotype-after-hematopoietic-stem-cell-transplantation-in-a/)

## Researcher topics

- [Parathyroid Disorders and Treatments](https://scholariq.org/topics/parathyroid-disorders-and-treatments/)
- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)
- [Magnesium in Health and Disease](https://scholariq.org/topics/magnesium-in-health-and-disease/)
- [Medical Imaging and Pathology Studies](https://scholariq.org/topics/medical-imaging-and-pathology-studies/)
- [Biomedical Research and Pathophysiology](https://scholariq.org/topics/biomedical-research-and-pathophysiology/)

## Researcher university

- [Indiana University Health](https://scholariq.org/institutions/indiana-university-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.